A landmark study by Tata Memorial Centre reveals immunotherapy drugs for head and neck cancer remain prohibitively expensive in India, costing ₹60-65 lakh for a six-month course. This highlights a critical gap in healthcare affordability and policy, as these life-saving treatments are not covered under Ayushman Bharat, forcing patients into catastrophic out-of-pocket expenditure.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›Drug Cost (6 months): Pembrolizumab: ₹60-65 lakh; Nivolumab: ₹12-15 lakh
- ›Cost-to-Income Ratio: Pembrolizumab cost is 80x average monthly income
- ›Target this Data: Pembrolizumab costs ₹60-65 lakh for a 6-month course.
- ›Target this Nodal Body: Tata Memorial Centre (TMC) and ACTREC conducted the study.
- ›Target this Policy Gap: Immunotherapy drugs are not covered under Ayushman Bharat PM-JAY.
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.